Logo image of AAPG

ASCENTAGE PHARMA GR-ADR (AAPG) Stock Fundamental Analysis

NASDAQ:AAPG - Nasdaq - ADR - Currency: USD

41.95  -0.86 (-2.01%)

Fundamental Rating

3

Taking everything into account, AAPG scores 3 out of 10 in our fundamental rating. AAPG was compared to 551 industry peers in the Biotechnology industry. Both the profitability and financial health of AAPG have multiple concerns. AAPG is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

AAPG had negative earnings in the past year.
In the past year AAPG has reported a negative cash flow from operations.
In the past 5 years AAPG always reported negative net income.
AAPG had a negative operating cash flow in each of the past 5 years.
AAPG Yearly Net Income VS EBIT VS OCF VS FCFAAPG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -500M -1B

1.2 Ratios

Looking at the Return On Assets, with a value of -15.49%, AAPG belongs to the top of the industry, outperforming 80.40% of the companies in the same industry.
Looking at the Return On Equity, with a value of -153.46%, AAPG is doing worse than 62.79% of the companies in the same industry.
Industry RankSector Rank
ROA -15.49%
ROE -153.46%
ROIC N/A
ROA(3y)-27.9%
ROA(5y)-29.89%
ROE(3y)-633.86%
ROE(5y)-409%
ROIC(3y)N/A
ROIC(5y)N/A
AAPG Yearly ROA, ROE, ROICAAPG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K -1.5K

1.3 Margins

AAPG's Gross Margin of 97.03% is amongst the best of the industry. AAPG outperforms 97.28% of its industry peers.
AAPG's Gross Margin has improved in the last couple of years.
AAPG does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 97.03%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.28%
GM growth 5Y2.55%
AAPG Yearly Profit, Operating, Gross MarginsAAPG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

3

2. Health

2.1 Basic Checks

AAPG does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AAPG has more shares outstanding
Compared to 5 years ago, AAPG has more shares outstanding
AAPG has a better debt/assets ratio than last year.
AAPG Yearly Shares OutstandingAAPG Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
AAPG Yearly Total Debt VS Total AssetsAAPG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

2.2 Solvency

AAPG has an Altman-Z score of 3.89. This indicates that AAPG is financially healthy and has little risk of bankruptcy at the moment.
AAPG has a better Altman-Z score (3.89) than 75.14% of its industry peers.
A Debt/Equity ratio of 4.46 is on the high side and indicates that AAPG has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 4.46, AAPG is doing worse than 83.30% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 4.46
Debt/FCF N/A
Altman-Z 3.89
ROIC/WACCN/A
WACC9.28%
AAPG Yearly LT Debt VS Equity VS FCFAAPG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B -1B 2B

2.3 Liquidity

A Current Ratio of 1.26 indicates that AAPG should not have too much problems paying its short term obligations.
AAPG has a Current ratio of 1.26. This is amonst the worse of the industry: AAPG underperforms 84.75% of its industry peers.
A Quick Ratio of 1.26 indicates that AAPG should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.26, AAPG is doing worse than 83.85% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.26
Quick Ratio 1.26
AAPG Yearly Current Assets VS Current LiabilitesAAPG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

7

3. Growth

3.1 Past

AAPG shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 61.43%, which is quite impressive.
Looking at the last year, AAPG shows a very strong growth in Revenue. The Revenue has grown by 341.77%.
AAPG shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 132.25% yearly.
EPS 1Y (TTM)61.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-0.86%
Revenue 1Y (TTM)341.77%
Revenue growth 3Y227.53%
Revenue growth 5Y132.25%
Sales Q2Q%97.9%

3.2 Future

Based on estimates for the next years, AAPG will show a very strong growth in Earnings Per Share. The EPS will grow by 24.96% on average per year.
The Revenue is expected to grow by 23.37% on average over the next years. This is a very strong growth
EPS Next Y-182.73%
EPS Next 2Y103.09%
EPS Next 3Y24.96%
EPS Next 5YN/A
Revenue Next Year-47.57%
Revenue Next 2Y62.63%
Revenue Next 3Y19.75%
Revenue Next 5Y23.37%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
AAPG Yearly Revenue VS EstimatesAAPG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B
AAPG Yearly EPS VS EstimatesAAPG Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 5 -5 -10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

AAPG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AAPG. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AAPG Price Earnings VS Forward Price EarningsAAPG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AAPG Per share dataAAPG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as AAPG's earnings are expected to grow with 24.96% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y103.09%
EPS Next 3Y24.96%

More info and screens

0

5. Dividend

5.1 Amount

AAPG does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ASCENTAGE PHARMA GR-ADR

NASDAQ:AAPG (8/8/2025, 8:17:40 PM)

41.95

-0.86 (-2.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-27 2025-03-27/bmo
Earnings (Next)N/A N/A
Inst Owners8.36%
Inst Owner Change2.43%
Ins Owners13.63%
Ins Owner ChangeN/A
Market Cap3.90B
Analysts86.15
Price Target37.97 (-9.49%)
Short Float %0.02%
Short Ratio1.28
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)8.7%
PT rev (3m)64.61%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)6.29%
EPS NY rev (3m)6.42%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)2.2%
Revenue NY rev (3m)2.2%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 28.57
P/FCF N/A
P/OCF N/A
P/B 106.04
P/tB 171.35
EV/EBITDA N/A
EPS(TTM)-0.59
EYN/A
EPS(NY)-1.45
Fwd EYN/A
FCF(TTM)-0.2
FCFYN/A
OCF(TTM)-0.17
OCFYN/A
SpS1.47
BVpS0.4
TBVpS0.24
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -15.49%
ROE -153.46%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 97.03%
FCFM N/A
ROA(3y)-27.9%
ROA(5y)-29.89%
ROE(3y)-633.86%
ROE(5y)-409%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.28%
GM growth 5Y2.55%
F-Score5
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 4.46
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 26.07%
Cap/Sales 2.48%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.26
Quick Ratio 1.26
Altman-Z 3.89
F-Score5
WACC9.28%
ROIC/WACCN/A
Cap/Depr(3y)161.69%
Cap/Depr(5y)588.72%
Cap/Sales(3y)47.03%
Cap/Sales(5y)745.08%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)61.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-0.86%
EPS Next Y-182.73%
EPS Next 2Y103.09%
EPS Next 3Y24.96%
EPS Next 5YN/A
Revenue 1Y (TTM)341.77%
Revenue growth 3Y227.53%
Revenue growth 5Y132.25%
Sales Q2Q%97.9%
Revenue Next Year-47.57%
Revenue Next 2Y62.63%
Revenue Next 3Y19.75%
Revenue Next 5Y23.37%
EBIT growth 1Y57.12%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-259.46%
EBIT Next 3Y26%
EBIT Next 5YN/A
FCF growth 1Y82.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y84.66%
OCF growth 3YN/A
OCF growth 5YN/A